Announcing Our Joint Development Agreement With Ori Biotech

For 20 years, Hitachi Chemical Advanced Therapeutics Solutions (HCATS) has helped clients to improve their cell-based therapy development and manufacturing processes. The client-focused mindset of our PCT global service platform allows our team to easily facilitate technology transfers, accelerate time to market, and reduce the costs and risks of clinical development programs.

And now the future looks even brighter thanks to our new relationship with Ori Biotech, Ltd.

Based in London and Philadelphia, Ori Biotech has developed a proprietary and flexible manufacturing platform that allows therapeutics developers to bring their products from pre-clinical process development to commercial scale manufacturing faster than ever. By combining this innovative technology platform with HCATS’s extensive experience in the cell therapy industry, the agreement will help cell and gene therapy developers to meet their increasingly critical manufacturing needs much more efficiently.

“We are very excited to announce our collaboration with Ori Biotech,” said Robert Preti, Ph. D  on the new relationship. “Using our 20 years of manufacturing experience to help advance Ori’s novel technology furthers our leadership in addressing the industry’s manufacturing challenges and accelerates the process of delivering our clients’ therapeutics to patients in need. We look forward to partnering with Ori and are confident this collaboration will help drive innovation throughout the industry.”

Jason C. Foster, CEO of Ori Biotech, agrees: “Our partnership with HCATS provides us an exciting opportunity to further develop and tailor our innovative CGT manufacturing platform technology for use in the real world. Leveraging HCATS’s longstanding experience in cell and gene therapy manufacturing helps us progress our technology much faster than we could on our own as we both work to bring the next generation of manufacturing solutions to market. Partnering with such a renowned and experienced contract manufacturer will help demonstrate the potential of our platform to address the significant challenges in large-scale production of these life-saving therapies.”

Thanks to this new relationship with Ori Biotech, our customers can expect even better results from the PCT service platform in the future. The PCT platform takes a Development by Design (DbD) approach to cell therapy manufacturing that emphasizes quality, scalability, sustainability, and cost of goods. Contact us today to find out how our experience and services can help your clinical development program position itself for long-term commercial viability.